Jamey Jacobs

IAGS (International Andreas Gruentzig Society) Proceedings

Drug-Eluting Stents: Current Limitations

08/01/2008

Jamey Jacobs ;

Tim A. Fischell , MD, FACC, FSCAI;

Jorge A. Belardi , MD, PhD;

Christopher U. Cates , MD;

Alfredo E. Rodriguez , MD, PhD;

Gregory Braden , MD;

Mike Cowley , MD;

David Sperling , MD;

Robert Fischell , MD;

Mike Cowley: Let’s begin with discussing case selection. Which patients should receive drug-eluting stents (DES)? Should they only receive one stent? Should we reserve DES for a select patient population? What should the approach be for...

Mike Cowley: Let’s begin with...

08/01/2008

Journal of Invasive Cardiology

IAGS (International Andreas Gruentzig Society) Proceedings

Industry Round Table: Where Are the New Devices?

08/01/2008

Kirk N. Garrett ;

Alex Martin ;

Marcia Schallehn ;

Matthew Jenusaitis ;

Matthew Pollman ;

Brian Firth , MD, PhD, MBA;

Jamey Jacobs ;

Brian Firth (Cordis Corporation): As you all probably know, Cordis, in its entirety, is a cardiovascular device company, and now a combination drug/device company. There are four major divisions: 1) Cordis Cardiology, 2) Cordis Endovascular,...

Brian Firth (Cordis...

08/01/2008

Journal of Invasive Cardiology